Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
European stocks fell firmly amid a global equity market pullback.
U.S. stock futures decline and shares in Europe fall amid a weak U.S. dollar, rising political tensions in the Gulf region and electoral risks in the U.K.